Complement in human disease: approved and up-and-coming therapeutics
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
SUMMARY The complement system is recognised as a protector against bloodborne pathogens and controller of normal immune and tissue homeostasis. However, dysregulated complement activity is associated with unwanted, or non-resolving, immune responses and inflammation which induce or exacerbate the pathogenesis of a broad range of inflammatory and autoimmune diseases. Although the merit of targeting complement clinically has long been acknowledged, the overall complement drug approval rate has been modest. However, the success of the humanised-anti C5 antibody eculizumab in effectively treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic syndrome has revitalised the field. Further, increased understanding of complement biology has led to the identification of novel targets for drug development and this, in combination with advances in drug discovery and development technologies, has resulted in a surge of interest in bringing new complement therapeutics into the clinic. At present, the rising number of approved drugs still almost exclusively target rare diseases, but the substantial pipeline of up-and-coming treatment options will likely provide opportunities to also expand the clinical targeting of complement to common diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne, D. R. W., Merkel, P. A., Schall, T. J., & Bekker, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023386 · Cited by 1,021
RetractedComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis
Absinta, M., Maric, D., Gharagozloo, M., Garton, T., Smith, M. D., Jin, J., Fitzgerald, K. C., Song, A., Liu, P., Lin, J.-P., et al. (2021) · Nature · doi:10.1038/s41586-021-03892-7 · Cited by 768
Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria
Hillmen, P., Szer, J., Weitz, I., Röth, A., Höchsmann, B., Panse, J., Usuki, K., Griffin, M., Kiladjian, J.-J., de Castro, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029073 · Cited by 440
The renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation
Bekassy, Z., Lopatko Fagerström, I., Bader, M., & Karpman, D. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-021-00634-8 · Cited by 167
Metadata
- Authors
- West, E. E., Woodruff, T., Fremeaux-Bacchi, V., & Kemper, C.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 403
- Issue
- 10424
- Pages
- 392-405
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4388686627
- Cited by
- 182
- References
- 7
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement in human disease: approved and up-and-coming therapeutics. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01524-6
- The paper
- West, E. E., Woodruff, T., Fremeaux-Bacchi, V., & Kemper, C. (2024). Complement in human disease: approved and up-and-coming therapeutics. The Lancet. https://doi.org/10.1016/s0140-6736(23)01524-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.